Autoimmune and inflammatory disorders and risk of malignant lymphomas - An update

Journal of Internal Medicine

Volumn 264, Issue 6, 2008, Pages 514-527

  Smedby, K E ^a   Askling, J ^a   Mariette, X ^b   Baecklund, E ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b BICÊTRE HOSPITAL   (France)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmunity; Chronic inflammation; Immune stimulation; Malignant lymphoma

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ABATACEPT; ADALIMUMAB; AZATHIOPRINE; B CELL ACTIVATING FACTOR; CHEMOKINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; B CELL LYMPHOMA; CANCER RISK; CARCINOGENESIS; CELIAC DISEASE; CONFERENCE PAPER; CROHN DISEASE; DERMATITIS HERPETIFORMIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INDICATION; DRUG SAFETY; ENTERITIS; EPSTEIN BARR VIRUS; FELTY SYNDROME; GENETIC RISK; HASHIMOTO DISEASE; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE SCLEROSIS; MYOSITIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SARCOIDOSIS; SIDE EFFECT; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTEMIC VASCULITIS; T CELL LYMPHOMA; ULCERATIVE COLITIS; VIRUS INFECTION;

ANTIGENS; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; INFLAMMATION; LYMPHOMA; RISK;

EID: 55949103220     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.02029.x     Document Type: Conference Paper

References (112)

1. Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985 78 : 29 32.
2. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996 32A : 1753 7.
3. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000 88 : 497 502.
4. Franklin J, Lunt M, Bunn D, Symmons DP, Silman AJ. Incidence of lymphoma in a large primary-care derived cohort of inflammatory polyarthritis. Ann Rheum Dis 2006 65 : 617 22.
5. Askling J, Fored CM, Baecklund E et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005 64 : 1414 20.
6. Smedby KE, Hjalgrim H, Askling J et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006 98 : 51 60.
7. Zhang Y, Holford TR, Leaderer B et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004 15 : 419 28.
8. Hemminki K, Li X, Sundquist K, Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology (Oxford) 2008 47 : 698 701.
9. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005 165 : 2337 44.
10. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006 65 : 796 803.
11. Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002 31 : 66 71.
12. Bernatsky S, Boivin JF, Joseph L et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005 52 : 1481 90.
13. Mellemkjaer L, Pfeiffer RM, Engels EA et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum 2008 58 : 657 66.
14. Ekstrom Smedby K, Vajdic CM, Falster M et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008 111 : 4029 38.
15. Askling J, Linet M, Gridley G, Halstensen TS, Ekstrom K, Ekbom A. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002 123 : 1428 35.
16. Catassi C, Fabiani E, Corrao G et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA 2002 287 : 1413 9.
17. West J, Logan RF, Smith CJ, Hubbard RB, Card TR. Malignancy and mortality in people with coeliac disease: population based cohort study. BMJ 2004 329 : 716 9.
18. Silano M, Volta U, Mecchia AM, Dessi M, Di Benedetto R, De Vincenzi M. Delayed diagnosis of coeliac disease increases cancer risk. BMC Gastroenterol 2007 7 : 8.
19. Sigurgeirsson B, Agnarsson BA, Lindelof B. Risk of lymphoma in patients with dermatitis herpetiformis. BMJ 1994 308 : 13 5.
20. Collin P, Pukkala E, Reunala T. Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. Gut 1996 38 : 528 30.
21. Kato I, Tajima K, Suchi T et al. Chronic thyroiditis as a risk factor of B-cell lymphoma in the thyroid gland. Jpn J Cancer Res 1985 76 : 1085 90.
22. Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 1985 312 : 601 4.
23. Askling J, Brandt L, Lapidus A et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005 54 : 617 22.
24. von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 2007 50 : 839 55.
25. Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001 117 : 1531 7.
26. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006 126 : 2194 201.
27. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005 52 : 2415 24.
28. Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A. Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 1999 160 : 1668 72.
29. Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006 54 : 692 701.
30. Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008 168 : 378 81.
31. Askling J, Baecklund E, Granath F et al. Anti-TNF therapy in RA and risk of malignant lymphomas Relative risks and time-trends in the Swedish Biologics Register. Ann Rheum Dis 2008 Epub ahead of print F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007 56 : 2886 95.
32. Jaffe ESHN, Stein H, Vardiman JW (ed Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Lyon : IARC Press, 2001.
33. Ekstrom-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma - a review. Acta Oncol 2006 45 : 258 71.
34. Cellier C, Delabesse E, Helmer C et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000 356 : 203 8.
35. Yamamoto K. Pathogenesis of Sjogren's syndrome. Autoimmun Rev 2003 2 : 13 8.
36. Landgren O, Engels EA, Pfeiffer RM et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006 98 : 1321 30.
37. Bernatsky S, Ramsey-Goldman R, Isenberg D et al. Hodgkin's lymphoma in systemic lupus erythematosus. Rheumatology (Oxford) 2007 46 : 830 2.
38. Royer B, Cazals-Hatem D, Sibilia J et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997 90 : 766 75.
39. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjogren's syndrome. Arthritis Rheum 1999 42 : 1765 72.
40. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol 2000 24 : 623 39.
41. Troch M, Woehrer S, Streubel B et al. Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma. Ann Oncol 2008 19 : 1336 9.
42. Baecklund E, Backlin C, Iliadou A et al. Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum 2006 54 : 3774 81.
43. Baecklund E, Natkunam Y, Backlin C et al. Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. Br J Haematol 2008 141 : 69 72.
44. Bernatsky S, Ramsey-Goldman R, Rajan R et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005 64 : 1507 9.
45. Lofstrom B, Backlin C, Sundstrom C, Ekbom A, Lundberg IE. A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 2007 66 : 1627 32.
46. Smedby KE, Akerman M, Hildebrand H, Glimelius B, Ekbom A, Askling J. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut 2005 54 : 54 9.
47. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003 139 : 1425 9.
48. Lindelof B, Eklund G, Liden S, Stern RS. The prevalence of malignant tumors in patients with psoriasis. J Am Acad Dermatol 1990 22 : 1056 60.
49. Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol 2001 137 : 778 83.
50. Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 2006 142 : 1132 5.
51. Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. J Am Acad Dermatol 2002 47 : 914 8.
52. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995 76 : 910 4.
53. Szekanecz E, Szamosi S, Gergely L, Keszthelyi P, Szekanecz Z, Szucs G. Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis. Clin Rheumatol 2008 27 : 1163 6.
54. Kanazawa N, Furukawa F. Autoinflammatory syndromes with a dermatological perspective. J Dermatol 2007 34 : 601 18.
55. Simsek S, van Leuven F, Bronsveld W, Ooms GH, Groeneveld AB, de Graaff CS. Unusual association of Hodgkin's disease and sarcoidosis. Neth J Med 2002 60 : 438 40.
56. Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol 2007 25 : 326 33.
57. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001 121 : 1080 7.
58. Farrell RJ, Ang Y, Kileen P et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000 47 : 514 9.
59. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005 54 : 1121 5.
60. Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007 13 : 1299 307.
61. Nielsen NM, Rostgaard K, Rasmussen S et al. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 2006 118 : 979 84.
62. Midgard R, Glattre E, Gronning M, Riise T, Edland A, Nyland H. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand 1996 93 : 411 5.
63. Sumelahti ML, Pukkala E, Hakama M. Cancer incidence in multiple sclerosis: a 35-year follow-up. Neuroepidemiology 2004 23 : 224 7.
64. Lebrun C, Debouverie M, Vermersch P et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler 2008 14 : 399 405.
65. Askling J, Klareskog L, Fored M, Blomqvist P, Feltelius N. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006 66 : 1184 7.
66. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002 100 : 82 5.
67. Faurschou M, Sorensen IJ, Mellemkjaer L et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008 35 : 100 5.
68. Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003 95 : 1797 800.
69. Swerdlow AJ, Laing SP, Qiao Z et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 2005 92 : 2070 5.
70. Hagler KT, Lynch JW Jr. Paraneoplastic manifestations of lymphoma. Clin Lymphoma 2004 5 : 29 36.
71. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992 326 : 363 7.
72. Hill CL, Zhang Y, Sigurgeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001 357 : 96 100.
73. Andras C, Ponyi A, Constantin T et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008 35 : 438 44.
74. Hauswirth AW, Skrabs C, Schutzinger C, Gaiger A, Lechner K, Jager U. Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-Hodgkin lymphomas. Leuk Lymphoma 2007 48 : 1139 49.
75. Soderberg KC, Jonsson F, Winqvist O, Hagmar L, Feychting M. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer 2006 42 : 3028 33.
76. Gridley G, Klippel JH, Hoover RN, Fraumeni JF Jr. Incidence of cancer among men with the Felty syndrome. Ann Intern Med 1994 120 : 35 9.
77. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002 46 : 741 7.
78. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 2000 29 : 296 304.
79. Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 2007 46 : 1359 62.
80. Ramos-Casals M, Solans R, Rosas J et al. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008 87 : 210 9.
81. King JK, Costenbader KH. Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). Clin Rheumatol 2007 26 : 1491 4.
82. Bernatsky S, Joseph L, Boivin JF et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 2008 67 : 74 9.
83. Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease - effect of a gluten free diet. Gut 1989 30 : 333 8.
84. Viljamaa M, Kaukinen K, Pukkala E, Hervonen K, Reunala T, Collin P. Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study. Dig Liver Dis 2006 38 : 374 80.
85. Rizzi R, Curci P, Delia M et al. Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 2008 Epub ahead of print OW, Van de Rijn M, Weiss LM et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. New Engl J Med 1993 328 : 1317 31.
86. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002 99 : 3909 15.
87. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004 50 : 1740 51.
88. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004 96 : 709 11.
89. Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG. No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control 2003 14 : 639 44.
90. Askling J, Klareskog L, Hjalgrim H, Baecklund E, Bjorkholm M, Ekbom A. Do steroids increase lymphoma risk? a case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis. Ann Rheum Dis 2005 64 : 1765 8.
91. Sorensen HT, Friis S, Norgard B et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003 88 : 1687 92.
92. Bernatsky S, Lee JL, Rahme E. Non-Hodgkin's lymphoma - meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology (Oxford) 2007 46 : 690 4.
93. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 295 : 2275 85.
94. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-Tumor Necrosis Factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2008 Epub ahead of print S, Solomon DH, Weinblatt ME et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006 54 : 2757 64.
95. Geborek P, Bladstrom A, Turesson C et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005 64 : 699 703.
96. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007 44 : 265 7.
97. Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2008 Epub ahead of print J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007 25 : S46 56.
98. Ekstrom K, Hjalgrim H, Brandt L et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003 48 : 963 70.
99. Andreone P, Gramenzi A, Lorenzini S et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003 163 : 1997 2004.
100. Gottenberg JE, Busson M, Cohen-Solal J et al. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. Ann Rheum Dis 2005 64 : 1050 5.
101. Bende RJ, Aarts WM, Riedl RG, de Jong D, Pals ST, van Noesel CJ. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005 201 : 1229 41.
102. Mariette X. Lymphomas complicating Sjogren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 2001 60 : 1007 10.
103. Schneider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999 189 : 1747 56.
104. Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007 19 : 327 36.
105. Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003 48 : 3475 86.
106. Mariette X, Roux S, Zhang J et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003 62 : 168 71.
107. Ittah M, Miceli-Richard C, Eric Gottenberg J et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006 8 : R51.
108. Ohata J, Zvaifler NJ, Nishio M et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005 174 : 864 70.
109. Novak AJ, Grote DM, Stenson M et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004 104 : 2247 53.
110. Sene D, Limal N, Ghillani-Dalbin P, Saadoun D, Piette JC, Cacoub P. Hepatitis C virus-associated B-cell proliferation - the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology (Oxford) 2007 46 : 65 9.
111. Barone F, Bombardieri M, Rosado MM et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 2008 180 : 5130 40.
112. Kallberg H, Padyukov L, Plenge RM et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007 80 : 867 75.